Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

Steven Boonen, J. D. Adachi, Z. Man, S. R. Cummings, K. Lippuner, O. Törring, John Christopher G. Gallagher, J. Farrerons, A. Wang, N. Franchimont, J. San Martin, A. Grauer, M. McClung

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Context: The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis. Objective: We evaluated the effect of denosumab on the incidence of new vertebral and hip fractures in subgroups of women at higher risk for these fractures. Design: FREEDOM was a 3-yr, randomized, double-blind, placebo-controlled, phase 3 trial. Participants and Setting: Postmenopausal women (N = 7808) with osteoporosis were enrolled at 213 study sites worldwide. Interventions: Subjects received sc denosumab (60 mg) or placebo every 6 months and daily supplements of calcium (≥1000 mg) and vitamin D (≥400 IU). Main Outcome Measures: This post hoc analysis evaluated fracture incidence in women with known risk factors for fractures including multiple and/or moderate or severe prevalent vertebral fractures, aged 75 yr or older, and/or femoral neck bone mineral density T-score of -2.5 or less. Results: Compared with placebo, denosumab significantly reduced the risk of new vertebral fractures in women with multiple and/or severe prevalent vertebral fractures (16.6% placebo vs. 7.5% denosumab; P <0.001). Similarly, denosumab significantly reduced the risk of hip fractures in subjects aged 75 yr or older (2.3% placebo vs. 0.9% denosumab; P <0.01) or with a baseline femoral neck bone mineral density T-score of -2.5 or less (2.8% placebo vs. 1.4% denosumab; P = 0.02). These risk reductions in higher-risk individuals were consistent with those seen in patients at lower risk of fracture. Conclusions: Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture. These results highlight the consistent antifracture efficacy of denosumab in patients with varying degrees of fracture risk.

Original languageEnglish
Pages (from-to)1727-1736
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

Hip Fractures
Incidence
Osteoporosis
Placebos
Therapeutics
Fracture Fixation
Femur Neck
Bone Density
Denosumab
Minerals
Bone
Risk Reduction Behavior
Vitamin D
Outcome Assessment (Health Care)
Calcium

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. / Boonen, Steven; Adachi, J. D.; Man, Z.; Cummings, S. R.; Lippuner, K.; Törring, O.; Gallagher, John Christopher G.; Farrerons, J.; Wang, A.; Franchimont, N.; San Martin, J.; Grauer, A.; McClung, M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 96, No. 6, 06.2011, p. 1727-1736.

Research output: Contribution to journalArticle

Boonen, S, Adachi, JD, Man, Z, Cummings, SR, Lippuner, K, Törring, O, Gallagher, JCG, Farrerons, J, Wang, A, Franchimont, N, San Martin, J, Grauer, A & McClung, M 2011, 'Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk', Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 6, pp. 1727-1736. https://doi.org/10.1210/jc.2010-2784
Boonen, Steven ; Adachi, J. D. ; Man, Z. ; Cummings, S. R. ; Lippuner, K. ; Törring, O. ; Gallagher, John Christopher G. ; Farrerons, J. ; Wang, A. ; Franchimont, N. ; San Martin, J. ; Grauer, A. ; McClung, M. / Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. In: Journal of Clinical Endocrinology and Metabolism. 2011 ; Vol. 96, No. 6. pp. 1727-1736.
@article{95930381524e4cf4ad1b04c70a477056,
title = "Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk",
abstract = "Context: The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis. Objective: We evaluated the effect of denosumab on the incidence of new vertebral and hip fractures in subgroups of women at higher risk for these fractures. Design: FREEDOM was a 3-yr, randomized, double-blind, placebo-controlled, phase 3 trial. Participants and Setting: Postmenopausal women (N = 7808) with osteoporosis were enrolled at 213 study sites worldwide. Interventions: Subjects received sc denosumab (60 mg) or placebo every 6 months and daily supplements of calcium (≥1000 mg) and vitamin D (≥400 IU). Main Outcome Measures: This post hoc analysis evaluated fracture incidence in women with known risk factors for fractures including multiple and/or moderate or severe prevalent vertebral fractures, aged 75 yr or older, and/or femoral neck bone mineral density T-score of -2.5 or less. Results: Compared with placebo, denosumab significantly reduced the risk of new vertebral fractures in women with multiple and/or severe prevalent vertebral fractures (16.6{\%} placebo vs. 7.5{\%} denosumab; P <0.001). Similarly, denosumab significantly reduced the risk of hip fractures in subjects aged 75 yr or older (2.3{\%} placebo vs. 0.9{\%} denosumab; P <0.01) or with a baseline femoral neck bone mineral density T-score of -2.5 or less (2.8{\%} placebo vs. 1.4{\%} denosumab; P = 0.02). These risk reductions in higher-risk individuals were consistent with those seen in patients at lower risk of fracture. Conclusions: Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture. These results highlight the consistent antifracture efficacy of denosumab in patients with varying degrees of fracture risk.",
author = "Steven Boonen and Adachi, {J. D.} and Z. Man and Cummings, {S. R.} and K. Lippuner and O. T{\"o}rring and Gallagher, {John Christopher G.} and J. Farrerons and A. Wang and N. Franchimont and {San Martin}, J. and A. Grauer and M. McClung",
year = "2011",
month = "6",
doi = "10.1210/jc.2010-2784",
language = "English",
volume = "96",
pages = "1727--1736",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

AU - Boonen, Steven

AU - Adachi, J. D.

AU - Man, Z.

AU - Cummings, S. R.

AU - Lippuner, K.

AU - Törring, O.

AU - Gallagher, John Christopher G.

AU - Farrerons, J.

AU - Wang, A.

AU - Franchimont, N.

AU - San Martin, J.

AU - Grauer, A.

AU - McClung, M.

PY - 2011/6

Y1 - 2011/6

N2 - Context: The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis. Objective: We evaluated the effect of denosumab on the incidence of new vertebral and hip fractures in subgroups of women at higher risk for these fractures. Design: FREEDOM was a 3-yr, randomized, double-blind, placebo-controlled, phase 3 trial. Participants and Setting: Postmenopausal women (N = 7808) with osteoporosis were enrolled at 213 study sites worldwide. Interventions: Subjects received sc denosumab (60 mg) or placebo every 6 months and daily supplements of calcium (≥1000 mg) and vitamin D (≥400 IU). Main Outcome Measures: This post hoc analysis evaluated fracture incidence in women with known risk factors for fractures including multiple and/or moderate or severe prevalent vertebral fractures, aged 75 yr or older, and/or femoral neck bone mineral density T-score of -2.5 or less. Results: Compared with placebo, denosumab significantly reduced the risk of new vertebral fractures in women with multiple and/or severe prevalent vertebral fractures (16.6% placebo vs. 7.5% denosumab; P <0.001). Similarly, denosumab significantly reduced the risk of hip fractures in subjects aged 75 yr or older (2.3% placebo vs. 0.9% denosumab; P <0.01) or with a baseline femoral neck bone mineral density T-score of -2.5 or less (2.8% placebo vs. 1.4% denosumab; P = 0.02). These risk reductions in higher-risk individuals were consistent with those seen in patients at lower risk of fracture. Conclusions: Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture. These results highlight the consistent antifracture efficacy of denosumab in patients with varying degrees of fracture risk.

AB - Context: The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis. Objective: We evaluated the effect of denosumab on the incidence of new vertebral and hip fractures in subgroups of women at higher risk for these fractures. Design: FREEDOM was a 3-yr, randomized, double-blind, placebo-controlled, phase 3 trial. Participants and Setting: Postmenopausal women (N = 7808) with osteoporosis were enrolled at 213 study sites worldwide. Interventions: Subjects received sc denosumab (60 mg) or placebo every 6 months and daily supplements of calcium (≥1000 mg) and vitamin D (≥400 IU). Main Outcome Measures: This post hoc analysis evaluated fracture incidence in women with known risk factors for fractures including multiple and/or moderate or severe prevalent vertebral fractures, aged 75 yr or older, and/or femoral neck bone mineral density T-score of -2.5 or less. Results: Compared with placebo, denosumab significantly reduced the risk of new vertebral fractures in women with multiple and/or severe prevalent vertebral fractures (16.6% placebo vs. 7.5% denosumab; P <0.001). Similarly, denosumab significantly reduced the risk of hip fractures in subjects aged 75 yr or older (2.3% placebo vs. 0.9% denosumab; P <0.01) or with a baseline femoral neck bone mineral density T-score of -2.5 or less (2.8% placebo vs. 1.4% denosumab; P = 0.02). These risk reductions in higher-risk individuals were consistent with those seen in patients at lower risk of fracture. Conclusions: Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture. These results highlight the consistent antifracture efficacy of denosumab in patients with varying degrees of fracture risk.

UR - http://www.scopus.com/inward/record.url?scp=79955117784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955117784&partnerID=8YFLogxK

U2 - 10.1210/jc.2010-2784

DO - 10.1210/jc.2010-2784

M3 - Article

VL - 96

SP - 1727

EP - 1736

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -